The identification of clinical candidate SB-480848: a potent inhibitor of lipoprotein-associated phospholipase A2

Blackie, Josie A.; Bloomer, Jackie C.; Brown, Murray J. B.; Cheng, Hung-Yuan; Hammond, Beverley; Hickey, Deirdre M. B.; Ife, Robert J.; Leach, Colin A.; Lewis, Vahn A.; Macphee, Colin H.; Milliner, Kevin J.; Moores, Kitty; Pinto, Ivan L.; Smith, Stephen A.; Stansfield, Ian; Stanway, Steven J.; Taylor, Maxine; Theobald, Colin J.

doi:10.1016/s0960-894x(03)00058-1

Cited by 119 publications

(95 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…This suppression of phagocytosis did not occur if treatment of oxidized apoptotic LA-HL60 cells with Lp-PLA 2 was conducted in the presence of a specific inhibitor of Lp-PLA 2 , SB-435495. 21,22 LC-MS analysis of phospholipids in Lp-PLA 2 -treated cells confirmed effective hydrolysis of PSox and accumulation of sn1-acyl-lyso-PS ( Figure 6 and Supplementary Figure S7). The amount of sn1-acyl-lyso-PS formed by Lp-PLA 2 treatment was 13 ± 2 pmol per 10 6 cells (8 mol % of total cell PS, Figure 6a, Supplementary Figure S7D).…”

Section: Resultsmentioning

confidence: 84%

Oxidatively modified phosphatidylserines on the surface of apoptotic cells are essential phagocytic ‘eat-me’ signals: cleavage and inhibition of phagocytosis by Lp-PLA2

et al. 2014

View full text Add to dashboard Cite

Diversified anionic phospholipids, phosphatidylserines (PS), externalized to the surface of apoptotic cells are universal phagocytic signals. However, the role of major PS metabolites, such as peroxidized species of PS (PSox) and lyso-PS, in the clearance of apoptotic cells has not been rigorously evaluated. Here, we demonstrate that H 2 O 2 was equally effective in inducing apoptosis and externalization of PS in naive HL60 cells and in cells enriched with oxidizable polyunsaturated species of PS (supplemented with linoleic acid (LA)). Despite this, the uptake of LA-supplemented cells by RAW264.7 and THP-1 macrophages was more than an order of magnitude more effective than that of naive cells. A similar stimulation of phagocytosis was observed with LA-enriched HL60 cells and Jurkat cells triggered to apoptosis with staurosporine. This was due to the presence of PSox on the surface of apoptotic LA-supplemented cells (but not of naive cells). This enhanced phagocytosis was dependent on activation of the intrinsic apoptotic pathway, as no stimulation of phagocytosis occurred in LA-enriched cells challenged with Fas antibody. Incubation of apoptotic cells with lipoprotein-associated phospholipase A 2 (Lp-PLA 2 ), a secreted enzyme with high specificity towards PSox, hydrolyzed peroxidized PS species in LA-supplemented cells resulting in the suppression of phagocytosis to the levels observed for naive cells. This suppression of phagocytosis by Lp-PLA 2 was blocked by a selective inhibitor of Lp-PLA 2 , SB-435495. Screening of possible receptor candidates revealed the ability of several PS receptors and bridging proteins to recognize both PS and PSox, albeit with diverse selectivity. We conclude that PSox is an effective phagocytic 'eat-me' signal that participates in the engulfment of cells undergoing intrinsic apoptosis.

show abstract

Section: Resultsmentioning

confidence: 84%

Oxidatively modified phosphatidylserines on the surface of apoptotic cells are essential phagocytic ‘eat-me’ signals: cleavage and inhibition of phagocytosis by Lp-PLA2

et al. 2014

View full text Add to dashboard Cite

show abstract

“…Lp-PLA 2 is therefore a useful biological marker that can help clinicians identify patients at higher risk than predicted based on traditional risk assessment alone [24]. [65]. It is only a weak inhibitor of secretory PLA2s [66].…”

Section: Consensus Panelsmentioning

confidence: 99%

Lp-PLA2- a novel risk factor for high-risk coronary and carotid artery disease

Epps

Wilensky

2010

Journal of Internal Medicine

View full text Add to dashboard Cite

show abstract

“…9 Darapladib is a potent and reversible oral inhibitor of lipoprotein-associated phospholipase A 2 . 10 In a swine model of atherosclerosis, darapladib reduced levels of lipoprotein-associated phospholipase A 2 in plaque, reduced the necrotic core area, and inhibited the development of lesions in coronary arteries. 11 Darapladib has also been shown to reduce lipoprotein-associated phospholipase A 2 activity in human carotid plaque.…”

mentioning

confidence: 99%

Darapladib for Preventing Ischemic Events in Stable Coronary Heart Disease

White¹,

Held²,

Stewart³

et al. 2014

N Engl J Med

477

149

View full text Add to dashboard Cite

BackgroundElevated lipoprotein-associated phospholipase A 2 activity promotes the development of vulnerable atherosclerotic plaques, and elevated plasma levels of this enzyme are associated with an increased risk of coronary events. Darapladib is a selective oral inhibitor of lipoprotein-associated phospholipase A 2 . MethodsIn a double-blind trial, we randomly assigned 15,828 patients with stable coronary heart disease to receive either once-daily darapladib (at a dose of 160 mg) or placebo. The primary end point was a composite of cardiovascular death, myocardial infarction, or stroke. Secondary end points included the components of the primary end point as well as major coronary events (death from coronary heart disease, myocardial infarction, or urgent coronary revascularization for myocardial ischemia) and total coronary events (death from coronary heart disease, myocardial infarction, hospitalization for unstable angina, or any coronary revascularization). ResultsDuring a median follow-up period of 3.7 years, the primary end point occurred in 769 of 7924 patients (9.7%) in the darapladib group and 819 of 7904 patients (10.4%) in the placebo group (hazard ratio in the darapladib group, 0.94; 95% confidence interval [CI], 0.85 to 1.03; P = 0.20). There were also no significant between-group differences in the rates of the individual components of the primary end point or in all-cause mortality. Darapladib, as compared with placebo, reduced the rate of major coronary events (9.3% vs. 10.3%; hazard ratio, 0.90; 95% CI, 0.82 to 1.00; P = 0.045) and total coronary events (14.6% vs. 16.1%; hazard ratio, 0.91; 95% CI, 0.84 to 0.98; P = 0.02). ConclusionsIn patients with stable coronary heart disease, darapladib did not significantly reduce the risk of the primary composite end point of cardiovascular death, myocardial infarction, or stroke. (Funded by GlaxoSmithKline; STABILITY ClinicalTrials.gov number, NCT00799903.)The Darapladib is a potent and reversible oral inhibitor of lipoprotein-associated phospholipase A 2 . 10 In a swine model of atherosclerosis, darapladib reduced levels of lipoprotein-associated phospholipase A 2 in plaque, reduced the necrotic core area, and inhibited the development of lesions in coronary arteries. 11 Darapladib has also been shown to reduce lipoprotein-associated phospholipase A 2 activity in human carotid plaque. 12 In the Integrated Biomarker and Imaging Study 2 (IBIS-2) involving patients with coronary heart disease, darapladib, as compared with placebo, halted the progression in the volume of the necrotic core of coronary-artery plaques (a secondary end point), as determined by intravascular ultrasonographic virtual histologic analysis during a 12-month period. 13 These findings suggest that darapladib could reduce the risk of events associated with coronary heart disease by altering the composition of atherosclerotic plaques to a less vulnerable state. 1 In the Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy (STABILITY) trial, we evaluated the clini...

show abstract

The identification of clinical candidate SB-480848: a potent inhibitor of lipoprotein-associated phospholipase A2

Cited by 119 publications

References 9 publications

Oxidatively modified phosphatidylserines on the surface of apoptotic cells are essential phagocytic ‘eat-me’ signals: cleavage and inhibition of phagocytosis by Lp-PLA2

Oxidatively modified phosphatidylserines on the surface of apoptotic cells are essential phagocytic ‘eat-me’ signals: cleavage and inhibition of phagocytosis by Lp-PLA2

Lp-PLA2- a novel risk factor for high-risk coronary and carotid artery disease

Darapladib for Preventing Ischemic Events in Stable Coronary Heart Disease

Contact Info

Product

Resources

About